|
業務類別
|
-- |
|
業務概覽
|
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its neurology development is focused on two areas: development of epigenetic regulation therapies to treat serious neurological diseases and development of novel engineered adeno-associated virus, or AAV, capsids to deliver its therapies to the intended neurological targets. The group's pipeline products are Small Fiber Neuropathy, Prion Disease, Tauopathies, ALS/FTD, Huntington's Disease, Fabry Disease, and Hemophilia A. |
| 公司地址
| 501 Canal Boulevard, Richmond, CA, USA, 94804 |
| 電話號碼
| +1 510 970-6000 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.sangamo.com |
| 員工數量
| 142 |
| Ms. Nathalie Dubois-Stringfellow, PhD |
Chief Development Officer |
美元 453.60K |
30/04/2025 |
| Mr. Scott B. Willoughby |
General Counsel and Corporate Secretary |
-- |
30/04/2025 |
| Mr. Nikunj Jain |
Interim Chief Financial Officer, Principal Accounting Officer, Vice President, Finance and Corporate Controller |
-- |
03/02/2026 |
| Ms. Amy Pooler, PhD |
Vice President and Head of Research |
-- |
19/04/2024 |
| Mr. Gregory Davis, PhD |
Head of Research and Technology |
-- |
30/04/2025 |
| Dr. Alexander Donald Macrae, M.B.,PhD |
Director, President and Chief Executive Officer |
美元 716.37K |
30/03/2026 |
|
|
| Mr. James R. Meyers |
Independent Director |
30/03/2026 |
| Dr. John H. Markels, PhD |
Independent Director |
30/03/2026 |
| Ms. Courtney Beers, PhD |
Independent Director |
30/03/2026 |
| Dr. Alexander Donald Macrae, M.B.,PhD |
Director, President and Chief Executive Officer |
30/03/2026 |
| Dr. Karen L. Smith, L.L.M.,M.B.A.,M.D.,PhD |
Independent Director |
30/03/2026 |
| Dr. Kenneth J. Hillan, Ch.B.,M.B. |
Independent Director |
30/03/2026 |
| Mr. Robert F. Carey |
Independent Director |
30/03/2026 |
| Ms. H. Stewart Parker |
Chairwoman of the Board |
30/03/2026 |
| Ms. Margaret A. Horn, J.D. |
Independent Director |
30/03/2026 |
|
|
|
|
